High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

被引:96
|
作者
Roh, Michael H. [2 ]
Yassin, Yosuf [3 ]
Miron, Alexander [3 ]
Mehra, Karishma K. [1 ,4 ]
Mehrad, Mitra [1 ,4 ]
Monte, Nicolas M. [1 ,4 ]
Mutter, George L. [1 ,4 ]
Nucci, Marisa R. [1 ,4 ]
Ning, Geng [1 ,4 ]
Mckeon, Frank D. [5 ]
Hirsch, Michelle S. [1 ,4 ]
Wa, Xian [1 ,4 ,6 ]
Crum, Christopher P. [1 ,4 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA
[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[3] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA
[6] ASTAR, Inst Med Biol, Singapore, Singapore
关键词
ovarian cancer; p16(ink4); p53; PTEN; PAX2; tubal intraepithelial carcinoma; TUBAL INTRAEPITHELIAL CARCINOMA; PELVIC SEROUS CARCINOMA; MUTATIONS; CANCER; PATHWAYS; TUMORS; WOMEN;
D O I
10.1038/modpathol.2010.119
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
High-grade endometrioid and serous carcinomas of the ovary and fallopian tube are responsible for the majority of cancer deaths and comprise a spectrum that includes early or localized (tubal intraepithelial carcinoma) and advanced (invasive or metastatic) disease. We subdivided a series of these tumors into three groups, (1) classic serous, (2) mixed serous and endometrioid and (3) endometrioid carcinomas and determined: (1) the frequencies of coexisting tubal intraepithelial carcinoma, (2) frequency of a dominant ovarian mass suggesting an ovarian origin and (3) immuno-localization of WT-1, p53, PTEN, PAX2 and p16(ink4). All tumors were analyzed for p53 mutations. Thirty six, 25 and 8% of groups 1-3 were associated with tubal intraepithelial carcinoma (P = 0.09) and 34, 45 and 62% predominated in one ovary (P = 0.028), respectively. Differences in frequencies of diffuse p53 immunostaining (85-93%), WT-1 (70-98%) and p16(ink4) positivity (69-75%) were not significant for all groups. Greater than 95% reduction in PAX2 and PTEN occurred in 67-75 and 5-12%, respectively; however, PAX2 and PTEN staining intensity, when present, was often heterogeneous, highlighting different tumor populations. PAX2 and PTEN expression were markedly reduced or absent in 12 of 12 and 4 of 12 tubal intraepithelial carcinomas. In summary, high-grade mullerian carcinomas share identical frequencies of altered or reduced expression of p53, PTEN and PAX2, all of which can be appreciated in tubal intraepithelial carcinomas. Because only a subset of these tumors appears to arise in the fallopian tube, attention to expression of these biomarkers in the ovary and other mullerian sites might facilitate the identification of other carcinogenic pathways. PAX2 and PTEN, in addition to p53 and p16(ink4), comprise a potentially important gene combination in high-grade pelvic carcinogenesis. Modern Pathology (2010) 23, 1316-1324; doi:10.1038/modpathol.2010.119; published online 18 June 2010
引用
收藏
页码:1316 / 1324
页数:9
相关论文
共 50 条
  • [41] IMMUNOREACTIVE P53 PROTEIN IN HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA
    HUMPHREY, PA
    SWANSON, PE
    PATHOLOGY RESEARCH AND PRACTICE, 1995, 191 (09) : 881 - 887
  • [42] A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy
    Casey, Laura
    Kobel, Martin
    Ganesan, Raji
    Tam, Simone
    Prasad, Rajeev
    Bohm, Steffen
    Lockley, Michelle
    Jeyarajah, Arjun J.
    Brockbank, Eleanor
    Faruqi, Asma
    Gilks, C. Blake
    Singh, Naveena
    HISTOPATHOLOGY, 2017, 71 (05) : 736 - 742
  • [43] p53 expression and relationship with MDM2 amplification in breast carcinomas
    Buyukpinarbasili, Nur
    Gucin, Zuhal
    Ersoy, Yeliz Emine
    Ilbak, Ayca
    Kadioglu, Huseyin
    Muslumanoglu, Mahmut
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2016, 21 : 29 - 34
  • [44] ELEVATED LEVELS OF MDM-2 AND P53 EXPRESSION ARE ASSOCIATED WITH HIGH-GRADE NON-HODGKINS-LYMPHOMAS
    FINNEGAN, MCM
    GOEPEL, JR
    ROYDS, J
    HANCOCK, BW
    GOYNS, MH
    CANCER LETTERS, 1994, 86 (02) : 215 - 221
  • [45] Correlation of poly(ADP-ribose)polymerase and p53 expression levels in high-grade lymphomas
    Menegazzi, M
    Scarpa, A
    de Prati, AC
    Menestrina, F
    Suzuki, H
    MOLECULAR CARCINOGENESIS, 1999, 25 (04) : 256 - 261
  • [46] The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
    Wojnarowicz, Paulina M.
    Oros, Kathleen Klein
    Quinn, Michael C. J.
    Arcand, Suzanna L.
    Gambaro, Karen
    Madore, Jason
    Birch, Ashley H.
    de Ladurantaye, Manon
    Rahimi, Kurosh
    Provencher, Diane M.
    Mes-Masson, Anne-Marie
    Greenwood, Celia M. T.
    Tonin, Patricia N.
    PLOS ONE, 2012, 7 (09):
  • [47] MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
    Blackman, Alexandra
    Rees, Amy C.
    Bowers, Robert R.
    Jones, Christian M.
    Vaena, Silvia G.
    Clark, Madison A.
    Carter, Shelby
    Villamor, Evan D.
    Evans, Della
    Emanuel, Anthony J.
    Fullbright, George
    O'Malley, Matthew S.
    Carpenter, Richard L.
    Long, David T.
    Spruill, Laura S.
    Romeo, Martin J.
    Orr, Brian C.
    Helke, Kristi L.
    Delaney, Joe R.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (09): : 2525 - 2538
  • [48] FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas
    Zhang, Xu-Yin
    Ding, Jing-Xin
    Tao, Xiang
    Hua, Ke-Qin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (01) : 350 - 354
  • [49] Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern
    Kim, Han-Na
    Woo, Ha Young
    Do, Sung-Im
    Kim, Hyun-Soo
    IN VIVO, 2019, 33 (05): : 1485 - 1492
  • [50] Analysis of p53 and c-erbB-2 expression in ovarian endometrioid carcinomas arising in endometriosis
    Prefumo, F
    Venturini, PL
    Fulcheri, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (01) : 83 - 88